TrialClinical endocrinology2019

Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Maria Fleseriu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.